secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001493152-26-012266
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech Q4 revenue $27.5M (+5% YoY); FY25 rev $103.1M (+19%); reaffirms FY26 guidance
--------------------------------------------------------------------------------

- Net revenue Q4 2025 $27.5M (+5% YoY); excluding $1.8M prior-year BIASURGE hurricane sales, growth was 13%.
- Full year 2025 net revenue $103.1M (+19% YoY); net loss from continuing ops narrowed to $0.4M from $1.9M.
- Adjusted EBITDA improved to $4.7M (Q4) and $17.0M (FY), vs $4.1M and $9.1M in prior year.
- Reaffirmed full year 2026 financial guidance; no specific numbers provided in the release.
- BIASURGE received Vizient Innovative Technology contract effective Jan 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315226012266/0001493152-26-012266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315226012266/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-012266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer